剂量间隔优化和法里西马布在与年龄相关的黄斑退化中的持续性:在现实世界临床实践中的观察性研究
Silvia Cornejo-Uixeda1, Joaquín Borrás-Blasco1, Alejandro Valcuende-Rosique2
1Pharmacy Department, Hospital Sagunto, Sagunto, Spain.
概括
法里西马布表现出极好的治疗持久性,并允许在新血管与年龄相关的黄斑变性 (nAMD) 患者在现实环境中延长剂量间隔. 这项研究证实了其在管理nAMD方面的有效性和耐受性.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经血管与年龄相关的黄斑变性 (nAMD) 在维持长期视力方面构成了重大挑战.
- 抗VEGF疗法是标准的,但对法里西马布等新药的真实数据至关重要.
研究的目的:
- 为了评估法里西马布在患有nAMD的患者中的实际治疗持久性和剂量间隔延长.
- 在临床环境中评估法里西马布的坚持和停止率.
主要方法:
- 一个回顾性观察性研究包括129名患者 (148只眼睛) 用法里西马布治疗.
- 在12个月内分析了剂量间隔,坚持 (MPR>80%) 和持久性.
- 卡普兰-梅尔生存分析估计治疗持续时间.
主要成果:
- 法里西马布的持续率很高:93%在6个月和12个月.
- 在12个月后,48.8%的未经治疗的患者和55.5%的预先治疗的患者实现了8-12周的剂量间隔.
- 平均持续时间为12.2个月,由于无效性而停止治疗的时间很小,没有严重的不良事件.
结论:
- 法里西马布在现实世界中表现出极好的持久性,并支持在nAMD管理中延长剂量间隔.
- 这项研究提供了第一个关于法里西马布在nAMD患者中的持久性现实世界的证据.
- 法里西马布是长期治疗nAMD的耐受性好且有效的选择.
相关概念视频
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
225
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
225
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
213
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
213
Drug Dosing: Geriatric Patients
217
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
217
Dosage Regimen: Fixed Dose
2.3K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.3K
Dosage Regimens: Designs and Approaches
250
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
250
Dosage Regimens: Partial Pharmacokinetic Parameters
144
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
144


